FIA586

FIA586 is an investigational small molecule drug developed by Novartis for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis in the liver. The precise mechanism of action for FIA586 has not been publicly defined. It was classified as a hepatoprotectant and considered a new molecular entity. Clinical development included phase I studies to assess pharmacokinetics, safety, and tolerability in both healthy volunteers and patients with mild to moderate hepatic impairment. As of 2023, Novartis discontinued further development of this compound as part of its strategic exit from NASH research[1][2][4][5].

Other names

FIA586FIA-586FIA 586